Inflammatory Biomarkers and Respiratory Function in Liver Transplant Patients: Findings from a Nationwide Cohort Analysis - Takeaways - MDSpire

Inflammatory Biomarkers and Respiratory Function in Liver Transplant Patients: Findings from a Nationwide Cohort Analysis

  • By

  • Nicoline Arentoft

  • Julie Høgh

  • Hans-Christian Pommergaard

  • Andreas Dehlbæk Knudsen

  • Annette Dam Fialla

  • Paul Suno Krohn

  • Niels Kristian Aagaard

  • Jens-Ulrik Stæhr Jensen

  • Jesper Rømhild Davidsen

  • Michael Perch

  • Allan Rasmussen

  • Susanne Dam Nielsen

  • April 28, 2026

  • 0 min

Share

  • 1

    Elevated hs-CRP levels are linked to impaired lung function in liver transplant recipients, indicating systemic inflammation's role in this population.

  • 2

    The study included 335 liver transplant recipients, revealing a prevalence of 11.6% for airflow limitation and 24.5% for preserved ratio impaired spirometry.

  • 3

    Median FEV1 and FVC values were 2790 mL and 3680 mL, respectively, with significant associations found between hs-CRP and reduced lung function.

  • 4

    After adjusting for age, sex, ethnicity, BMI, and smoking, hs-CRP >3 mg/L was associated with lower FEV1 and FVC, highlighting its clinical relevance.

  • 5

    This study is the first to explore the relationship between circulating inflammatory markers and lung function in liver transplant recipients.

Original Source(s)

Inflammatory Biomarkers and Respiratory Function in Liver Transplant Patients: Findings from a Nationwide Cohort Analysis

  • by Nicoline Arentoft, Julie Høgh, Hans-Christian Pommergaard, Andreas Dehlbæk Knudsen, Annette Dam Fialla, Paul Suno Krohn, Niels Kristian Aagaard, Jens-Ulrik Stæhr Jensen, Jesper Rømhild Davidsen, Michael Perch, Allan Rasmussen, Susanne Dam Nielsen

  • April 28, 2026

Related Content

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.

Lung Disease Complicates RA Care

Patients with chronic lung disease had numerically lower remission rates and substantially more serious adverse events in a 5-year Japanese registry study of late-onset rheumatoid arthritis.

FDA Clears Breztri for Asthma Use

Single-inhaler triple therapy improved lung function vs dual therapy in phase 3 trials and showed rapid onset without new safety signals.